LONDON (ShareCast) - SkyePharma is the day’s top riser after the pharmaceutical firm said its development and marketing partner Mundipharma has reported positive results from two Phase III clinical studies for the European development programme for asthma treatment Flutiform.

“We are delighted that along with the three Phase III pivotal efficacy studies conducted for NDA submission, we now have two further Phase III studies for European regulatory submission that have met their primary endpoints,” said chief operating officer Ken Cunningham.

Earlier this month, SkyePharma said its third Phase III efficacy study evaluating Flutiform has met its primary endpoints.

Kewill was also up after it said it has continued to make good progress since it announced full-year results last month, in line with expectations.

“The board is mindful of macro economic conditions, in particular in the US, however we have not yet seen any material impact on our pipelines, which remain very healthy, and support our expectations of growth over the next financial year,” said the group.

FTSE TechMARK - Risers
Skyepharma (SKP) 3.10p +14.81%
Sinclair Pharma (SPH) 37.50p +14.50%
Renovo Group (RNVO) 53.00p +13.37%
BTG (BGC) 185.75p +10.57%
Vernalis (VER) 4.95p +8.55%
Morse (MOR) 47.50p +4.40%
Ark Therapeutics (AKT) 49.25p +3.68%
Robotic Technology (RTS) 4.50p +2.86%
Kewill Systems (KWL) 86.00p +2.38%
Trafficmaster (TFC) 32.50p +1.56%

FTSE TechMARK - Fallers
Corin Group (CRG) 154.00p -10.47%
Computacenter (CCC) 133.50p -9.80%
Alizyme (AZM) 14.75p -9.23%
Oxford Biomedica (OXB) 9.50p -7.32%
Axon Group (AXO) 429.00p -6.02%
NXT (NTX) 12.50p -5.66%
E2V Technologies (E2V) 220.00p -5.38%
Wolfson Microelectronics (WLF) 120.50p -4.74%
Anite Group (AIE) 36.25p -3.97%
Optos (OPTS) 155.00p -3.73%

• News Channel